HELPER T CELL SUBPOPULATION ACTIVITIES IN HIV DISEASE

艾滋病毒疾病的一个主要并发症是呼吸系统疾病恶化， 其通常是过敏源性的。 这是一项试点研究， IgE介导的呼吸道感染率与HIV血清转换相关 和疾病进展，并测试标准过敏原的安全性， 这些HIV+患者的免疫治疗方案。一些患者已经 入组研究，其中一人已接受超过12个月的监测， AIT. 他有严重的常年性过敏性鼻炎病史， 对药物治疗有反应。 他开始每周接受AIT治疗， 用于CD 4群体、病毒载量和体外细胞因子产生。 结果 显示他的CD 4计数保持稳定，血浆病毒载量保持稳定 不可检测 他的体外破伤风诱导的IFNg水平增加， 他的IL-4和IL-10水平保持相对不变。 临床 反应是显着的，他的症状评分下降到0， 一年，不再需要常规药物。 这些数据 这表明AIT可能对选定HIV+患者有用， 需要进行更大规模的对照试验，以确定哪些HIV+患者 可能会从这种疗法中受益。

A major complication of HIV disease is worsening respiratory conditions, which are often of allergic origin. This is a pilot study to identify prevalence of IgE-mediated respiratory correlated with HIV seroconversion and disease progression, and to test the safety of a standard allergen immunotherapy regimen in these HIV+ patients.Several patients have been enrolled in the study, and one has been monitored for over 12 months on AIT. He had a history of severe perennial allergic rhinitis poorly responsive to medical therapy. He started weekly AIT and was monitored for CD4 populations, viral load and in vitro cytokine production. Results showed his CD4 count remained stable and his plasma viral load remained undetectable. His in vitro tetanus-induced IFNg levels increased while his IL-4 and IL-10 levels remained relatively unchanged. Clinical response was remarkable, with his symptom scores demising to 0 over the year and need for regular medications no longer necessary. These data suggest that AIT may have utility in selected HIV+ patients and support the need for a larger controlled trial to establish which HIV+ patients might be expected to benefit from this therapy.